Agilent Technologies, Inc. (NYSE:A) Position Cut by Simplicity Wealth LLC

Simplicity Wealth LLC trimmed its holdings in Agilent Technologies, Inc. (NYSE:A) by 72.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,684 shares of the medical research company’s stock after selling 4,371 shares during the quarter. Simplicity Wealth LLC’s holdings in Agilent Technologies were worth $250,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Crewe Advisors LLC grew its holdings in Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after buying an additional 101 shares in the last quarter. Ridgewood Investments LLC acquired a new stake in Agilent Technologies in the second quarter worth approximately $29,000. Rise Advisors LLC lifted its position in Agilent Technologies by 527.8% in the first quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after purchasing an additional 190 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in Agilent Technologies in the second quarter worth approximately $39,000. Finally, Riverview Trust Co acquired a new stake in Agilent Technologies in the first quarter worth approximately $41,000. 87.42% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Citigroup upped their target price on Agilent Technologies from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Bank of America upped their target price on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research report on Thursday, August 22nd. Wells Fargo & Company started coverage on Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price objective for the company. Wolfe Research downgraded Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research report on Thursday, June 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $151.00 price objective on shares of Agilent Technologies in a research report on Monday, August 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $143.64.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Dominique Grau sold 9,990 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,953 shares of company stock valued at $2,013,630. 0.33% of the stock is owned by insiders.

Agilent Technologies Price Performance

A opened at $144.25 on Tuesday. The stock has a fifty day moving average of $140.70 and a 200-day moving average of $138.87. The firm has a market capitalization of $42.09 billion, a P/E ratio of 34.10, a PEG ratio of 6.96 and a beta of 1.05. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $155.35. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same period in the prior year, the business posted $1.43 earnings per share. Agilent Technologies’s revenue for the quarter was down 5.6% compared to the same quarter last year. Equities analysts forecast that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st will be paid a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Tuesday, October 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 22.22%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.